Long-term outcomes in antineutrophil cytoplasmic autoantibody–positive eosinophilic granulomatosis with polyangiitis patients with renal involvement: a retrospective study of 14 Chinese patients

Table 3 Treatment and follow-up of patients with EGPA

Case	Treatment		Follow-up (months)	Measurements at last visit
Case	Induction	Maintenance	Follow-up (months)	Hb (g/dl)	EOS (%)	Upro (g/24 h)	SCr (mg/dl)	MPO-ANCA (RU/ml)
1	MP/CTX (6g^a)	Aza	8	11.4	5	0.50	1.58	320
2	MP/CTX (5.8 g)	Aza	83	13.4	6	0.10	0.56	0
3	MP/CTX (6 g)	Aza	63	13.0	2	2.04	1.21	0
4	Pred/CTX (6.4 g)	TW	26	13.7	2	1.02	2.46	0
5	Pred/MMF	Aza	28	12.1	2	0.75	2.19	31.8
6	IA/MP/MMF	Aza	56	11.1	3	0.14	2.26	63.3
7	IA/MP/MMF	Aza	41	11.4	0	1.86	2.41	21
8	IA/MP/MMF	TW	46	12.8	3	0.12	1.79	135
9	MP/MMF	TW	50	13.7	1	0.2	2.30	89.9
10	MP/MMF	Pred	6	6.6	14	0.72	MHD	82.5
11	MP/Pred	TW	47	14.0	2	0.45	1.83	0
12	MP/Pred	TW	12	12.6	0	1.83	2.40	156
13	IA/MP/Pred	Pred	5	10.0	1	1.38	MHD	133.7
14^b	IA/MP	-	0	-	-	-	-	-

EGPA eosinophilic granulomatosis with polyangiitis, MHD maintenance hemodialysis Pred prednisone, MP methylprednisolone, Pred prednisone, CTX cyclophosphamide, MMF mycophenolate mofetil, IA immunoadsorption, TW Tripterygium wilfordii polyglycoside, AZA azathioprine. ^atotal dose of CTX, ^bthe patient died

ISSN: 1471-2369